48. At what age did you first use estrogens other than Premarin pills?. Although nearly critically ill is dependent premarin occurred. VALUE OF CLINICAL PHARMACISTS TO FAMILY MEDICINE RESIDENCY PROGRAMS: A SURVEY OF FAMILY MEDICINE RESIDENTS AND FACULTY Lindsey A. Baugh * , Tracy L. Bottorff, Emily C. Papineau Community Health Network, 1500 N Ritter Ave, Indianapolis, IN, 46219 lbaugh ecommunity Background and Purpose: Clinical pharmacists have been involved with Family Medicine Residency Programs FMRPs ; since the 1970s. A recent survey revealed that pharmacists are involved in about 30% of FMRPs nationwide. The pharmacists surveyed reported that the majority of their time is spent in patient care activities and teaching family medicine residents and pharmacy students. It has been demonstrated that physicians in family medicine clinics generally have a positive perception of pharmacy encounters related to patient care activities; however, data describing FMRP's perceptions of clinical pharmacist activities, including teaching, are lacking. The primary outcome of this study is to determine the value of clinical pharmacists involved in FMRPs and the perceived value of adding a clinical pharmacist for programs in which one is not involved. Methodology: A survey was developed regarding the value of inpatient and outpatient clinical pharmacists. Survey respondents are asked to indicate the level of value placed on teaching and patient care activities typically performed by clinical pharmacists and rank the top three most important. Respondents not currently utilizing clinical pharmacists are questioned regarding whether adding clinical pharmacists would be valuable to their FMRP. Demographic data type of institution, year in the program, years in practice, professional designation, location of medical degree, age, and gender ; are also collected. Family medicine residents and faculty of all programs accredited by the Accreditation Council for Graduate Medical Education ACGME ; and or American Osteopathic Association AOA ; in Indiana will be included. The surveys will be administered at the Indiana Academy of Family Physicians Faculty Development Workshop and Resident's Day and Research Forum in March 2007 and via mail. Statistical methods will be used to summarize and compare data. Results: Data collection will commence, pending investigational review board approval. Conclusion: The conclusion of the study will be presented at the Great Lakes Pharmacy Residency Conference. Learning Objectives: Describe the current status of clinical pharmacy involvement with FMRPs. List the two most common activities performed by clinical pharmacists involved in FMRPs. Self Assessment Questions: True or False? The number of clinical pharmacists involved in FMRPs has decreased over the last several years. True or False? Clinical pharmacists involved in FMRPs spend the majority of their time educating medical residents and pharmacy students, for example, premarin effects. Also know as progynova without rx prescriptions progynova fda rx progynova non rx rx market progynova freedom rx progynova pharmacy progynova buy online progynova free rx oestradiol valerate on med-store oestradiol valerate at r-xlist estrace rx med discount price estrace estrace fda rx premarin estrogen, estrace, estraderm ; -without prescription 25mg-84 tabs manufacturer-wyeth ayerst eedom rx pharm. Portia, 31 potass citrate citric acid, 40 potassium acetate, 40 potassium chloride, 40 potassium citrate, 40 potassium effervescent, 40 potassium phosphate, 40 PRANDIN, 17 PRAVACHOL, 21 pravastatin, 21 prazosin, 19 PRECOSE, 17 PRED MILD, 36 PRED-G, 36 prednisolone, 10, 34, 35, prednisone, 10, 34 PREFEST, 29 PRELONE, 10 PREMARIN, 29 PREMARIN VAGINAL, 29 premasol, 40 PREMPHASE, 29 PREMPRO, 29 prenatal vitamins Rx only ; , 40 PREVACID CAPSULE, 27 PREVACID I.V., 27 PREVACID NAPRAPAC, 27 PREVACID SOLUTION, 27 PREVACID SUSPENSION, 27 prevalite, 26 PREVIDENT, 40 previfem, 31 PREVPAC PATIENT PACK, 27 PREZISTA, 16 PRIALT, 3 PRIFTIN, 3 prilosec otc, 27 PRIMAQUINE, 14 PA Prior Authorization and prempro.
P 0.05, tp 0.01, tp 0.001: Premarin, or Premarin and Provera vs. no estrogen. women had lower levels of insulin. This difference was unexplained by age and obesity as defined by body mass index ; , or by smoking, alcohol, or exercise. Women in this cohort who were taking estrogen did not differ from women who were not taking estrogen with regard to pre-prescription health status.8 The difference in insulin levels by estrogen use is also unlikely to be due to differential prescription of estrogen for women with known diabetes, who were excluded from this analysis; their rate of use was similar 39% in diabetic vs. 4 1 % in nondiabetic women ; , and, among those with diabetes, there was a lower fasting plasma glucose 5.8 mmol l in the 26 estrogen-using women compared to 6.8 mmol l in the 40 nonestrogen-using women, p 0.05 ; . The 12% prevalence of diabetes excluded from this study ; in this sample is similar to that reported in a national sample of older women 17 based on the same criteria Obese adults often have hyperinsulinemia with or without hyperglycemia.1819 Estrogen may have a weightlimiting effect in postmenopausal women.20-21 This could reduce obesity-associated insulin resistance and result in lower plasma insulin levels. However, the animal work cited above and this study also suggest that the longterm effect of sex hormones on glucoregulation may be independent of body weight. Some studies suggest that estrogens and progestins play a different role in the maintenance of 0-cell function in the female; in an isolated islet cell model, glucose-stimulated insulin release was reduced by ovariectomy and restored by estrogen, progesterone, or the combination; in addition, the number of 0-cells was reduced by ovariectomy, and medication with hormone reversed this effect.14 These results demonstrating that estrogen use is associated with signtficantty lower basal insulin levels independently of glucose levels and other confounding factors suggest that estrogen therapy can reduce insulin resistance in women. The observation here that the largest observed differences were for fasting insulin is compatible with this hypothesis, since fasting insulin levels correlate well with insulin resistance determined by insulin damp techniques.22 Clinical trials will be needed to confirm these results and determine which estrogen replacement regimen has the most desirable effect on glucose tolerance and insulin resistance. Given the increasing frequency of long-term postmenopausal estrogen use, the issue is of considerable potential clinical significance. The relationship to.

When available, FDA approved generic drugs are to be used in all situations, regardless of the brand name indicated. The brand names listed are for reference use only, and do not denote coverage, unless specifically noted. Greater economy is realized through the use of generic equivalents. This policy is not meant to preclude or supplant any state statutes that may exist. All drugs that are or become available generically are subject to review by CMSPs pharmacy and therapeutics review process. CMSP approves such multisource drugs for addition to the MAC list based on the following criteria: A minimum of one "A" rated source of the product. A FDA Rating for generic equivalency. Review by CMSP for efficacy and safety. Certain drug products with complex pharmacokinetics, dosage forms, narrow therapeutic efficacy or where blood level maintenance is crucial will not be subject to substitution. These products are: Coumadin EFF 6 20 03 ; Dilantin Lanoxin EFF 6 20 03 ; Premarin Neoral Oral Solution Synthroid and prevacid. Table 8. Adverse Reactions % ; Reported with the Single Entity Vaginal Estrogens20, 24, 35-41 Adverse Event Estradiol Estradiol Estradiol Estrogens, Estradiol Estradiol Estrace ; Estring ; Acetate Conjugated Vagifem ; Estrogel ; Femring ; Equine Premarin ; Body as a whole Headache 13 7-10 20.2 a a Back pain pain 6 4-6 7.1 Infection 17.3 Flu syndrome 5.4 Asthenia 4.8 Digestive System Nausea 3 2-3 6.0 a a a Flatulence 6.5 Diarrhea 4.2 Gastroenteritis 1-3 a a a a Abdominal 4 7.7 a a a pain Nervous System Insomnia 4 Emotional lability Nervousness 2.4 a a Depression 3.0 a a a Anxiety 1.8 Respiratory System Upper 5 4 respiratory tract infection bronchitis ; Sinusitis 4 2-4 3.6 Rhinitis 2.4 Cardiovascular System Palpitations 0.6 Skin and appendages Rash 7.1 a a a Pruritus 4.8 Nutritional Weight change 2.4 a a a Urogenital System Breast pain 1 6-11 12.5 a a a Vaginal 8-10 1.2 a a a bleeding Dysmenorrhea a Metrorrhea 3.0 a a a Endometrial 1.8 disorder Vaginitis 8.9 Pap smear 5.4 suspicious Vaginal 5 1-2 a discomfort pain. Assessment of member health risk has become a critical need of healthcare organizations. Health plans and other managed care organizations are increasingly adopting tools that allow them to better understand and predict health risks of the members they enroll and the potential medical care costs associated with those risks. Member health risk can vary for a number of reasons, including a person's current health, genetic make-up, socio-economic status, and environment. Whether to support accurate payments, obtain meaningful comparisons of provider performance or identify patients of highest risk, sound methods of health risk assessment are critical tools for any health care organization. Adjusting for differences in health risk can be thought of as a two-step process. The first step, risk assessment, involves the measurement of the expected health care costs or utilization of an individual or groups of individuals. Risk adjustment is the mechanism for adjusting for differences in risk, as measured by the risk assessment. In all applications, risk adjustment will only be as good as the underlying risk assessment method. In this paper, we describe an innovative approach to health risk assessment called Pharmacy Risk Groups PRGsTM ; . The PRGs were originally developed in 2003 and utilize an individual's pharmaceutical prescriptions and demographic information to assess prospective health risk. PRGs are designed to assist organizations that do not have access to medical claims or want to perform more timely health risk assessment. Although medical claims can provide advantages in measuring patient risk, a pharmacy-based model provides the following benefits: Minimal Data requirements Enrollment data and member pharmacy claims are all that is needed to run PRGs. Timely prediction Very short claim lag and completion time allows users to assess member's health risk in a timely manner as pharmacy claims are usually available for analysis within two weeks for most organizations. Clean and accurate information Clinical information obtained from pharmacy data is typically reliable and complete. More frequent risk assessment Because pharmacy data is readily available, requires fewer resources to extract and is relatively clean, organizations can perform risk assessment in more frequent intervals than is practical with medical claims data as often as on a nightly basis, if relevant. Cost effective As PRGs are easy to implement and operate, minimal IT and data warehouse resources are required and prilosec. The August 30 Decision. Some TRIPS-plus provisions in the bilateral and regional trade agreement are: a. Patent-DRA 'linkage' requirement b. No marketing approval without consent of patent holder c. 5 yeas data exclusivity d. Compensation for unreasonable delays in patent grant in the form of extension of patent duration beyond 20 years. e. Restrictions on right to determine grounds for compulsory licensing. Despite these challenges, some countries have actually implemented the flexibilities provided by TRIPS to ensure access to drugs at the national Level. For example, in October 2003 Malaysia issued a Government Use authorization for importing drugs from India, to be used by the government for HIV AIDS treatment. Mozambique issued Compulsory Licensing in March 2004 and Zambia in September 2004.

The lowest effective dose of PROVERA has not been determined. HOW SUPPLIED PROVERA Tablets are available in the following strengths and package sizes: 2.5 mg scored, round, orange ; Bottles of 30 NDC 0009-0064-06 Bottles of 100 NDC 0009-0064-04 5 mg scored, hexagonal, white ; Bottles of 100 NDC 0009-0286-03 10 mg scored, round, white ; Bottles of 100 NDC 0009-0050-02 Bottles of 500 NDC 0009-0050-11 Store at controlled room temperature 20 to 25C 68 to 77F ; [see USP]. "Keep out of reach of children" REFERENCES 1. Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275: 370-375, 1996. Woodruff JD, Pickar JH: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens Premarin ; with medroxyprogesterone acetate or conjugated estrogens alone The Menopause Study Group ; . J Obstet Gynecol 170: 1213-1223, 1994. Speroff L, Rowan J, Symons J, et al: The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy CHART Study ; JAMA 276: 1397-1403, 1996. The results of the NIH Women's Health Initiative estrogen plus progestin clinical trial were reported in the Journal of the American Medical Association, 288: 321-333, 2002. The results of the NIH Women's Health Initiative Memory Study estrogen plus progestin clinical trial were reported in the Journal of the American Medical Association, 289: 2663-2672, 2003. The results of the NIH Women's Health Initiative estrogen-alone clinical trial were reported in the Journal of the American Medical Association, 2004; 291: 1701-1712. The results of the NIH Women's Health Initiative Memory Study estrogen-alone clinical trial were reported in the Journal of the American Medical Association, 2004; 291: 2947-2958. Rx only and prinivil. Continued from previous page peripheral axonal branching, dendritic and terminal arborisa-tion, regulation of neurotransmitter production, regulation of neuro-peptide levels, establishment of functional synapses, long-term control of metabolic functions and local regulation of nerve terminal growth. What do we know about the safety and efficacy of recombinant human nerve growth factor in its use for HIV-related PN? The study: 271 patients were enrolled in a multi-centre, placebo-controlled, randomized trial ACTG 291 ; with HIVassociated neuropathy. They were randomized to receive either placebo, 0.1ug kg rhNGF, or 0.3 ug kg rhNGF self-administered by subcutaneous injection twice weekly for 18 weeks. Outcome measures included changes in self-reported neuropathic pain measured on the Gracely Pain Scale ; , prescription analgesic use, quantitative sensory testing, neurologic examination and global improvement as assessed by patient and blinded investigator. The results: There was a significant difference favouring the active treatment arms with respect to both average and maximum pain intensity scores from baseline. The higher dose rhNGF 0.3 ug kg ; had a greater effect than the lower dose 0.1 ug kg ; . The overall treatment effect on daily average neuropathic pain was 0.1 for the lower dose and 0.17 for the higher dose, representing a proximate change from moderate to mild neuropathic pain. Positive effects were also seen on both patient and investigator global pain assessments. There were no treatment effects on quantitative sensor y testing, self-reported mood, or the use of concomitant analgesics. The study drug was well-tolerated with no measurable changes in HIV RNA levels or other laboratory indices. Injection-site hyperalgesia was the most frequent adverse effect, but was not a frequent reason for study discontinuation. Neuromyalgia was noted in a small number of cases, usually as a re.
Cream estrogen premarin 11 jul 2007 : 14 utc premarin video : take this condition and procardia.

Other symptoms of low blood sugar such as dizziness, hunger, or sweating are unaffected by these drugs, for example, premarin settlement.

Fiona and also, most insurance will not cover the cost of nhrt components ie: tri-est and compounded progesterone ; whereas they will cover the more usual prescriptions of premarin, provera, etc this difference is quite costly, from my experience and promethazine. Significantly greater total client volume and a significantly greater family planning client volume in each of the three study settings total client volume: Pakistan coeff 5 0.317, s.e 5 0.112, Bihar coeff 5 0.939, s.e 5 0.077, Ethiopia coeff 5 0.935, s.e 5 0.224; family planning client volume: Pakistan coeff 5 0.895, s.e 5 0.121, Bihar coeff 5 0.758, s.e 5 0.088, Ethiopia coeff 5 0.999, s.e 5 0.181 ; . Only in Pakistan is franchise membership significantly associated with a greater volume of reproductive health clients coeff 5 0.799, s.e 5 0.173 ; . Family planning clients make up only a small percentage of the total clients surveyed in each country; Pakistan 13.0 percent, Ethiopia 14 percent, and Bihar 3.5 percent. Figure 1 shows the additional number of clients that are associated with franchise membership, calculated as the antilogs of the coefficients of the logged outcomes, and after controlling for the other independent variables in the models. Membership in a franchise network is associated with an additional 2.4 family planning clients in Pakistan, 2.1 in Bihar, and 2.7 in Ethiopia. In Pakistan, membership in a franchise network is associated with 2.2 additional reproductive health clients, because premarin alternatives.
A canadian drugs pharmacy will require a valid prescription for premarin medications ordered and propoxyphene.

Contain higher levels of USP progesterone than found in FDA-approved commercial products, a clear violation of prescription regulations. We need a balanced, medically-sound approach to address all of these issues. And, we need enforcement of existing regulations to curb abuses. We do not need further restriction. Further restricting the compounding pharmacies will put them out of business. Is that what we really want? Overview of the Issues Facing Us: Wyeth, maker of Premarin, the estrogen mixture derived from pregnant mares' urine, and Prempro horse estrogens plus a potent synthetic progestin ; , filed a "Citizens Petition" with the FDA to restrict compounding and dispensing of bioidentical hormones i.e., estradiol, progesterone, and testosterone ; for women needing hormone therapy. A number of national women's health organizations, with long-standing research and other supportive financial ties to Wyeth, have filed statements with the FDA in support of Wyeth's petition. The International Academy of Compounding Pharmacists filed comments rebutting Wyeth's claims. Thousands of consumers have filed letters in opposition to Wyeth's petition. Much of the furor arose following the July 2002 press release of adverse results from The Women's Health Initiative WHI ; , using horse-derived estrogen and synthetic progestin Wyeth's product Prempro ; : more blood clots, heart attacks, strokes and breast cancer in the Prempro group. In 2004, the estrogen-only arm of the study, using Premarin Wyeth's product ; , was stopped a year early due to increased risk of stroke. But there was no increased risk of breast cancer or heart attack in the estrogen-only group. Press coverage of the Women's Health Initiative WHI ; caused panic and fear in women everywhere. Women in droves abruptly stopped hormones. Wyeth lost almost two-thirds of its annual sales of Premarin, Prempro, Premphase. Sales dropped from over billion in 2001 prior to release of WHI outcomes ; to 880 million in 2004. After the WHI, doctors advised women to stop hormones or not start hormone therapy for menopausal symptoms. Women suffering return of symptoms besieged physicians with phone calls asking "What do I do now?" Popular consumer books gained media attention, and described "bioidentical hormones, " supposedly only made by compounding pharmacies. Compounding pharmacies began increased marketing of these options for patients who were understandably concerned about taking Premarin or Prempro after the reported WHI risks. Many consumer-oriented publications, and physicians, ignored FDA-approved bioidentical hormone products!

An analysis of the company ’ s gross sales, by product, subject to each of these provisions for the years ended december 31, 2004 and 2003 , follows: the company had accrual balances related to its managed care rebates, medicaid rebate obligations and chargebacks of 0 million and 2 million, as of december 31, 2004 and 2003 , respectively. Drug interaction - premarin and fosamax question: my doctor prescribed premarin 625 mg to be taken along with fosamax 10 mg to prevent heart attacks and alzheimer's disease.

P 98450 110272 98396 PRAMOSONE LOTION 1% PRAMOSONE LOTION 1% PRAMOSONE LOTION 2.5% PRAMOSONE LOTION 2.5% PRAMOSONE OINTMENT 2.5% PRANDIN 0.5 MG WHITE PRANDIN 1 MG YELLOW PRANDIN 2 MG RED PRAVACHOL 10 MG DACO ; PRAVACHOL 20 MG DACO ; PRAVACHOL 40 MG DACO ; PRAVACHOL 80 MG DACO ; PRAVIGARD PAC 20 325MG PRAVIGARD PAC 20 81MG PRAVIGARD PAC 40 325MG PRAVIGARD PAC 40 81MG PRAVIGARD PAC 80 325MG PRAVIGARD PAC 80 81MG PRECARE PRENATAL CHEW U D PRECARE PRENATAL MULTIVITAMIN PRECISION QID STRIPS PRECOSE 100 MG PRECOSE 25 MG PRECOSE 50 MG PRED FORTE OPHT SOLUTION PRED FORTE OPHT SOLUTION PRED MILD OPHT SOLUTION PREDNISONE 1 MG PREDNISONE 1 MG PREFEST PREMARIN 0.3 MG DACO ; PREMARIN 0.45 MG DACO ; PREMARIN 0.625 MG DACO ; PREMARIN 0.625 MG DACO ; PREMARIN 0.9 MG DACO ; PREMARIN 1.25 MG DACO ; PREMARIN 1.25 MG DACO ; PREMARIN O.3 MG DACO ; PREMARIN VAG CREAM W APPL PREMPHASE 0.625 5MG 3 TAB PREMPRO .625 2.5 MG DACO ; ROSA PREMPRO .625 5 MG DACO ; AZUL PRENA-CAP PRENATE ELITE PREVACID 15 MG DACO ; PREVACID 15 MG U DACO ; PREVACID 15 MG DACO ; PREVACID 30 MG DACO ; PREVACID SUSP ORAL 15 MG DACO ; PREVACID SUSP ORAL 30 MG DACO.
0.1 mg 24HR TierS-- CLIMARA estradiol Transdermal NonPatch Formulary Formulary Alternative s ; : estradiol, estropipate, Menest, Premarin, Alora 0.045-0.015 Tier 5-- CLIMARAPRO estradiol-levonorgestrel mg Non Transdermal Patch Formulary.

Buy cheap Premarin Senate Committee on Health and Human Services percent living donors ; than would be expected from their representation on the waiting list 5.1 percent ; .25 and prempro. Drug use is a voluntary, non-violent activity, and shoul. Report any unusual vaginal bleeding right away while you are taking premarin.

Premarin drug interactions PREEMPTION--Contd. Food, Drug, and Cosmetic Act --Medical Device Amendments. See Medical Device Amendments to Food, Drug, and Cosmetic Act, this heading --Vioxx, Tex. law presumes that warnings approved by FDA adequate Tex. Dist. Ct. ; , 410 Labor Management Relations Act, football uniform design claims in NFL player's death not preempted S.D. Ohio ; , 160 Medical Device Amendments to Food, Drug, and Cosmetic Act --Artificial spinal discs, deviation from standard claim allowed Mass. Super. Ct. ; , 389 --Breast implants, negligent design and warranty claims preempted W.D. Ky. ; , 284 --Cardiac catheters, FDA premarket approval triggers preemption U.S., brief filed ; , 535; rev grant ; , 612 --Contact lens solution, warning claim preempted, other claims dismissed D. Utah ; , 308 --Defibrillators - -Battery flaw, MDL plaintiffs ask to disallow interlocutory appeal of preemption ruling D. Minn. ; , 83; motions to dismiss denied, 593 - -FDA compliance discovery allowed, most claims preempted E.D. Mo. ; , 306 --Drug delivery pump, state claims preempted N.D. W. Va. ; , 372 --Heart valves, state claim preempted U.S., rev sought ; , 378 --Investigational device exemption not sought, some claims allowed D.D.C. ; , 377 Mercury in canned tuna public health advisory, warning claims preempted D.N.J. ; , 61 National Childhood Vaccine Injury Act, mercurybased preservatives, most claims barred against makers E.D. Pa. ; , 415 New Drug Approval process, bone cement, injury claims preempted W.D. La. ; , 8 Occupational Safety and Health Act, material handling equipment rollover, state claim not preempted 3d Cir. ; , 374 PREMARIN Heeding presumption applies in breast cancer claim N.J. Super. Ct. ; , 615 PREMPRO Heeding presumption applies in breast cancer claim N.J. Super. Ct. ; , 615 Medical monitoring class decertified, review denied Fla. ; , 167 Multidistrict litigation --Punitive claim, Wyeth seeks to strike E.D. Ark. ; , 84 --Rush, woman to challenge defense verdict E.D. Ark. ; , 186 Ohio couple awarded M, cause of breast cancer Pa. Ct. C.P. ; , 185; verdict and award thrown out, 578 Tex., warning claim preempted by drug labeling rules Tex. Dist. Ct. ; , 135 PRESCRIPTION DRUG USER FEE ACT PDUFA ; Food and Drug Administration Revitalization Act. See LEGISLATION, FEDERAL, S 1082 House panel supports bill, hearing comments seek clarity on post-market issues, 506 Reauthorization priority, draft agreement includes money for drug safety efforts, 65; hearing held, 189; FDA chief questioned at House hearing, 240; lawmakers look to attach other bills to expedite, 264; FDA sends Congress revised plan, 331 PRESCRIPTION DRUGS See DRUGS; specific products PRINTING PRESSES Expert with only general knowledge of machine works rejected, defense judgment E.D.N.Y. ; , 458. 2005 by Excerpta Medica Inc. All rights reserved. The American Journal of Cardiology Vol. 95 March 1, 2005. Cheap Premarin online Progestin-only birth control pills, often called "mini pills, " are used to prevent pregnancy. "Regular" birth control pills contain two hormones: estrogen ESS-tre-jen ; and progestin pro-JESS-ten ; . Mini pills contain progestin only. These hormones are like those made by your body, because premarin sales. Cheap Premarin

Tab. 1. Structure, distribution, functional effects and pharmacology of 5-HT receptors [5, 6, 9, 21, continued from the previous page.
Wellness stars simple steps to better health all premarin currently is derived from estrogens extracted from pregnant mares' urine.
At baseline, estradiol levels were low and equivalent in all 3 groups reflecting the postmenopausal status and the absence of estrogen supplementation Figure ; . There were no significant associations between baseline estradiol levels and any of the 7 neuropsychological measures. An identical pattern was observed for estrone. During treatment, patients receiving placebo maintained uniformly low levels of estradiol averaging approximately 5 pg mL pmol L ; Figure ; . Individuals receiving 0.625 mg d of Premarin had mean estradiol levels of approximately 20 pg mL pmol L ; and those receiving 1.25 mg d of Premarin had levels averaging 35 to 40 128-147 pmol L ; . All estradiol levels returned to pretreatment values by 3 months after discontinuing Premarin treatment. A similar pattern was seen with estrone with levels averaging approximately 175 pg mL 648 pmol L ; while receiving 0.625 mg d of Premarin and 350 pg mL 1295 pmol L ; while receiving 1.25 mg d of Premarin data not shown ; . Across all treated patients, levels of estradiol ranged from 0 to more than 100 pg mL 0 367 pmol L ; . This spread in estradiol levels allowed us to examine the change scores between cognitive measures across a wide range of plasma estradiol levels. There were no significant associations between the MMSE or ADAS-Cog change score and plasma estradiol change at either 2 or 12 months after initiating therapy. There was a significant negative association between change in delayed recall and change in estradiol level at 12 months but not at 2 months Table ; . Further exploration of this relationship revealed that this association was largely dependent on 3 outliers in which large increases in plasma estradiol levels 55, 62, and 73 pg mL [202, 227, and 268 pmol L, respectively] ; were associated with decreases in delayed word recall at 12 months -4, -4, and -3 words, respectively ; . After removal of the 3 outliers, the association between estradiol level and delayed recall disappeared P .75 ; . There were no significant associations between the change scores in estradiol level and word recall, Letter Cancellation, Trails A, or Letter Fluency test results at 2 or months Table ; . Repeating the analyses with estrone revealed an identical pattern with a significant negative association existing at 12 months only for the change in delayed recall and the change in estrone level P .05 ; that disappeared when the 3 outliers were removed P .88 ; . In addition, there was a separate and independent main effect of apolipoprotein E on change in the delayed recall test results at 12 months for both estradiol and estrone that also disappeared when the 3 outliers were removed.